CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CT radiomics can predict disease progression within 6 months after chimeric antigen receptor-modified T-cell therapy in relapsed/refractory B-cell non-Hodgkin's lymphoma patients.
CT radiomics can predict disease progression within 6 months after chimeric antigen receptor-modified T-cell therapy in relapsed/refractory B-cell non-Hodgkin's lymphoma patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
基于 CECT 的影像组学特征可用于预测 R/R B-NHL 患者接受 CAR-T 细胞治疗后 6 个月内的疾病进展,且来自多个病灶的影像组学特征可能具有更好的预测效能。不同的机器学习算法在预测性能上可能未显示出显著差异。
通过对比增强计算机断层扫描(CECT)检查得出的放射组学指标,预测复发/难治性(R/R)B细胞非霍奇金淋巴瘤(B-NHL)患者在接受嵌合抗原受体修饰(CAR)T细胞治疗后6个月内的疾病进展。
回顾性分析了70例在接受CAR-T 细胞治疗前进行了CECT的R/R B-NHL患者。从CECT图像中总共分割出297个病灶的感兴趣体积。无疾病进展和有疾病进展的患者分别被分配到第1组和第2组。分别使用训练集的特征,通过三种机器学习算法构建了放射组学和联合预测模型。此外,分别基于多病灶和最大病灶的放射组学特征构建了预测模型。
在测试集中,三种机器学习算法的联合模型和影像组学模型的曲线下面积(AUC)之间未观察到显著差异(均 p>0.05)。机器学习算法的差异未显著影响模型的预测性能。基于多病灶影像组学特征构建的影像组学模型和联合模型,其预测性能优于采用最大病灶影像组学特征的模型(联合模型间比较均 p<0.05)。
Seventy R/R B-NHL patients who underwent CECT before treatment with CAR T-cells were examined retrospectively. In total, 297 volumes of interest for lesions were segmented from CECT images. Patients without and with disease progression were assigned to groups 1 and 2, respectively. Radiomic and combined predictive models were constructed by three machine-learning algorithms using features from the training set, respectively. Furthermore, predictive models were constructed based on multi-lesion-based and largest-lesion-based radiomic features, respectively.
In the test set, no marked differences were observed between the areas under the curves (AUCs) of the combined and radiomic models for all three machine-learning algorithms (all p>0.05). Differences in machine-learning algorithms did not significantly affect the predictive performances of the models. Radiomics and combined models constructed with multi-lesion-based radiomic features showed better predictive performances than those applying largest-lesion-based radiomic features (all p<0.05 for comparisons between combined models).
CECT-based radiomic features may be applied to predict disease progression in R/R B-NHL patients within 6 months after CAR T-cell treatment, and radiomic features from multiple lesions may have better predictive efficacy. Different machine-learning algorithms may not show significant differences in prediction performance.
MEMBER ACCOUNT
登录成功会直接打开下一页。